Screener
Summit Therapeutics SMMT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other current liabilities | (1,135) | (1,046) |
| Other non-current liabilities | (33) | 25 |
| Operating lease right-of-use assets and lease liabilities, net | 365 | 25 |
| Net cash used in operating activities | (122,291) | (61,168) |
| Cash flows from investing activities: | ||
| Maturities and sales of short-term investments | 177,293 | 160,532 |
| Purchase of short-term investments | (177,286) | — |
| Purchases of property and equipment | (245) | (422) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's operating cash flow?
- Summit Therapeutics (SMMT) reported operating cash flow of -$122.29M in Q1 2026.
- How has Summit Therapeutics's operating cash flow changed year-over-year?
- Summit Therapeutics's operating cash flow decreased by 99.9% year-over-year, from -$61.17M to -$122.29M.
- What is the long-term trend for Summit Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Summit Therapeutics's operating cash flow has grown at a 64.5% compound annual growth rate (CAGR), from -$72.59M to -$322.93M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Summit Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude